Table 2.

Trials of Treg cell therapy for liver transplantation.

Institution	Trial ID	Type of trial	n	Timing of infusion after transplantation	Induction therapy	Cell isolation	Specificity	Type of Tregs	Current status
Hokkaido	UMIN000015789	Phase I/II	10	2 weeks	Cyclophosphamide	No	Donor specific	Treg enriched donor-specific-anergic T cells	Published in 2016
UCSF	NCT02188719	Phase I	15	2–6 months	ATG	Yes	Donor specific	Donor alloantigen reactive Treg	Terminated
Beth Israel	NCT02739412	Phase II	7	2–4 years	–	–	–	Endogenous Treg by low dose IL-2 injection	Active, not recruiting
Nanjing	NCT 01624077	Phase I	1	–	–	No	Polyclonal	In vitro induced Treg	Unknown
UCSF	NCT02474199	Phase I/II	14	2–6 years	ATG	Yes	Donor specific	Donor-alloantigen reactive Treg	Completed
King's College	NCT02166177	Phase I/II	9	2 months	ATG	Yes	Polyclonal	Autologous Treg	Completed
MGH	NCT03577431	Phase I/II	9	2-6 months	Cyclophosphamide	Yes	Donor specific	Alloantigen-reactive Treg	Recruiting

Treg, regulatory T cell; UCSF, University of California, San Francisco; ATG, anti-thymocyte globulin; MGH, Massachusetts General Hospital.